RRC ID 82656
Author Dileep KV, Sakai N, Ihara K, Nakata A, Ito A, Sivaraman DM, Yip CW, Shin JW, Yoshida M, Shirouzu M, Zhang KYJ.
Title Identification of benzimidazole-6-carboxamide based inhibitors of secretory glutaminyl cyclase for the treatment of Alzheimer's disease.
Journal Int J Biol Macromol
Abstract The formation of the pyroglutamate variant of amyloid beta (pGlu-Aβ), which is extremely hydrophobic, rapidly aggregating, and highly neurotoxic, is mediated by the action of secretory glutaminyl cyclase (sQC). The pGlu-Aβ often acts as a seed for the aggregation of the full length Aβ and contributes to the overall load of Aβ plaques in Alzheimer's disease (AD). Therefore, inhibiting sQC is a potential approach to limit the formation of pGlu-Aβ and to modify the progression of AD. This study presents two novel molecules containing benzimidazole-6-carboxamide, namely LSB-09 and LSB-24, as promising sQC inhibitors. These inhibitors demonstrated moderate toxicity in human neuroblastoma cell lines and possessed IC50 values in the micromolar range (40 and 4 μM for LSB-09 and LSB-24, respectively). Additionally, the X-ray crystal structure of the sQC-LSB-09 complex revealed a unique binding mode, and a systematic computational investigation elucidated the binding mode for LSB-24. The binding mode of these two benzimidazole-6-carboxamide inhibitors offers a potential platform for designing attractive lead candidates against sQC.
Volume 293
Pages 139320
Published 2025-3-1
DOI 10.1016/j.ijbiomac.2024.139320
PII S0141-8130(24)10131-6
PMID 39740711
MeSH Alzheimer Disease* / drug therapy Alzheimer Disease* / metabolism Aminoacyltransferases* / antagonists & inhibitors Aminoacyltransferases* / chemistry Aminoacyltransferases* / metabolism Benzimidazoles* / chemistry Benzimidazoles* / pharmacology Cell Line, Tumor Enzyme Inhibitors* / chemistry Enzyme Inhibitors* / pharmacology Humans Molecular Docking Simulation Protein Binding
IF 5.162
Resource
Human and Animal Cells NH-12(RCB2108)